Convenience and Cost-aspects of a New 1-step Reconstitution Injectable Artesunate Compared to Conventional 2-step Injectable Artesunate for the Treatment of Severe Falciparum Malaria: a Multi-centre Study
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 200
- 试验地点
- 1
- 主要终点
- Time to administration of treatment comparing 1-step vs. conventional 2-step parenteral artesunate formulations
研究概览
简要总结
The objectives of this study contains 3 parts: (1) a comparison of 1-step parenteral artesunate (AS) versus conventional 2-step parenteral artesunate in patients with severe malaria to assess the feasibility of administration, parasite and fever clearance times in two countries, (2) a quantification of convenience and costs of the new 1-step artesunate parenteral formulation versus the conventional formulation in a randomised study, (3) A cost analysis of 1-step parenteral artesunate using data from Part 1 & Part 2. This will assess health facility-level costs, and also health system costs to encompass all costs of a potential change from conventional to 1-step artesunate, including re-training, materials, and drug replacement.
The conventional formulation of injectable artesunate requires a 2-step reconstitution and dilution of the artesunate hemisuccinate powder. A new formulation of injectable artesunate has been developed by Fosun Pharma requiring a simpler 1-step reconstitution. Bioequivalence of the new formulation to the conventional formulation.
For part 1, a total number of participants of this study would be 200 participants, estimated 100 per site will be recruited. For part 2, a total number of 40 semi-structured interviews with study staff, health staff, policy makers, and stake holders; and survey/questionnaires with 150 health staff.
详细描述
Study design:
Part 1
A comparison of 1-step parenteral artesunate vs. conventional 2-step parenteral artesunate in patients with severe malaria to assess the feasibility of administration, parasite and fever clearance times of 1-step parenteral artesunate to conventional artesunate in 2 countries. Patients with severe malaria will be enrolled and randomly allocated to treatment with conventional injectable artesunate or 1-step injectable artesunate. A physical examination will be performed daily and every six hours on indication. Vital signs rec-orded hourly for unstable patients, then 6 hourly for stabilised patients, and at each follow-up visit. A symptom questionnaire will be taken daily to help identify adverse events. Patients will be asked to come back for a follow-up visit at day 7, 14, 21 and 28. Patients will not be followed up longer. In case of unresolved important sequelae at day 28, the patient will be followed and treated longer in order to provide the appropriate clinical care.
A Time and Motion study will record the time to prepare the artesunate solution for injection and administer treatment, number of actions performed to prepare treatment, and consumables used. Clinical, parasitological, and laboratory assessments will be recorded while patients are admitted in hospital and then weekly up to day 28 to assess recovery and determine final status.
Part 2
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 3 Months 至 16 Years(Child)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
1-step Artesunate parenteral arm
Argesun (Artesunate 60 mg)
干预措施: Argesun 60mg (1 step parenteral artesunate) (Drug)
2-step Artesunate parenteral arm
Artesun (Artesunate 60 mg)
干预措施: Artesun 60mg (2-step parenteral artesunate) (Drug)
结局指标
主要结局
Time to administration of treatment comparing 1-step vs. conventional 2-step parenteral artesunate formulations
时间窗: 3 days
Time to administration of treatment comparing 1-step vs. conventional 2-step parenteral artesunate formulations (by time-and-motion methods).
Costs of administration of 1-step vs. conventional 2-step parenteral artesunate formulations
时间窗: 3 days
Costs of administration of 1-step vs. conventional 2-step parenteral artesunate formulations at health facility, and at health system level.
次要结局
- Practicability assessment of 1-step formulation of parenteral artesunate(45 minutes)
- Satisfaction assessment of 1-step formulation of parenteral artesunate(45 minutes)
- Implementation perspective assessment of 1-step formulation of parenteral artesunate(45 minutes)
